According to the report published by Allied Market Research, the global schizophrenia drugs market generated $7.16 billion in 2021 and is estimated to hit $12.53 billion by 2031, registering a CAGR of 5.8% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/17470
Key Market Players
Pfizer Inc., AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGAA, Minerva Neurosciences, Novartis AG, Reliance, Sumitomo Dainippon, Takeda Pharmaceuticals, Vanda Pharmaceuticals, Alkermes
Schizophrenia Drugs Market Report Highlights
Treatment
- Oral
- Injectable
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Therapeutic Class
- Second Generation
- Third Generation
- Other
Get detailed COVID-19 impact analysis on the Schizophrenia Drugs Market- https://www.alliedmarketresearch.com/request-for-customization/17470?reqfor=covid